Machine learning to identify and prioritise drug targets
Science, Technology and innovation Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
2023
sciencetechnology-and-innovation
Pfizer joins the Open Targets consortium
Announcements, Science Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
2022
announcementsscience
The human genome, data sharing, and drug discovery: a career profile with Ian Dunham
Lab Matters Ian Dunham walks us through his career so far including working on the human genome project, seeing his work on the cover of Nature and his current role as Director of Open Targets.
2021
lab-matters
Six Ways to Protect the Planet Against Pandemics*
Events EMBL will host a conference to look at the state of the pandemic, lessons learned, and ways to improve pandemic preparedness. Here’s a sneak peek into what promises to be another interesting and informative EMBL conference.
2021
events
The PROTACtable genome – a new route to drug discovery
Science Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
2021
science
EMBL provides key infrastructure for COVID-19 drug screening project
Science EMBL Hamburg’s integrated structural biology facility has contributed to the success of a large-scale SARS-CoV-2 study
2021
science
Repurposing drugs to manage COVID-19 progression
Science Researchers use large-scale human genetic studies to identify drug targets important for managing COVID-19 in its early stages
2021
science
Repurposing drugs for a pan-coronavirus treatment
Science Scientists from the Beltrao Group at EMBL-EBI and collaborators identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, three pathogenic coronaviruses. They also found potential drugs that could be repurposed as COVID-19 treatments, and against emerging coronavirus strains in the…
2020
science
What COVID-19 is teaching us
Events The virtual EMBL Conference ‘SARS-CoV-2: Towards a New Era in Infection Research’ explored the importance of fundamental research, collaboration, and data science in containing the SARS-CoV-2 pandemic, and discussed opportunities to improve our response to pandemics in the future.
2020
events
Welcome: Ellie McDonagh
Lab Matters Open Targets welcomes new Informatics Science Director
2020
lab-matters
Understanding the influenza virus
Science The infectious disease commonly known as flu is caused by the influenza virus. It spreads around the world in seasonal outbreaks, causing millions of infections and hundreds of thousands of deaths each year. Stephen Cusack, Head of EMBL Grenoble, has been studying different aspects of the influenza…
2020
science
EMBL and Tara: Hamburg
Events EMBL Hamburg and Tara raise awareness of the risks of microplastic pollution and global infection
2019
events
Prioritising cancer drug targets using CRISPR
Science Large CRISPR screen prioritises hundreds of promising genes for personalised cancer treatment
2019
science
New Open Targets Director appointed
Lab Matters New director drives drug discovery partnership forward
2019
lab-matters
Sanofi joins Open Targets
Lab Matters Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open Targets
2018
lab-matters
Promega joins EMBL’s Corporate Partnership Programme
Lab Matters EMBL and Promega collaborate to train young scientists
2018
lab-matters
Celgene joins Open Targets
Lab Matters New partner strengthens drug discovery collaboration
2018
lab-matters
Futures: Unravelling influenza
Science ERC grantee Stephen Cusack shares his vision for the next ten years
2017
science
Takeda joins drug target discovery initiative
Lab Matters Takeda joins pioneering public-private drug discover collaboration Open Targets
2017
lab-matters
Fighting disease with structural biology
Alumni Alumnus Michael Parker talks about his career, research highlights and how EMBL has played a role
2017
alumni
Welcome, Andrew Leach
Science Q&A with EMBL-EBI's Head of Chemical Biology data services
2017
science
Futures: Phosphatases
Science ERC grantee Maja Köhn shares her vision for the next ten years
2017
science
Structure of key system for TB infection
Science EMBL scientists add crucial knowledge to understanding of the bacterium that causes tuberculosis
2017
science
Biogen joins CTTV
Lab Matters Pioneering target validation collaboration expands to accelerate drug discovery research.
2016
lab-matters
Learning from the linker
Science Mature cells can be reprogrammed to pluripotency and thus regain the ability to divide and differentiate into specialized cell types. Although these so-called induced pluripotent stem cells (iPS cells) represent a milestone in stem cell research, many of the biochemical processes that underlie…
2013
science
Open access drug discovery database launches with half a million compounds
Science ChEMBLdb, a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets, launches today with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new…
2010
science
Open access to large-scale drug discovery data
Lab Matters The Wellcome Trust has awarded £4.7 million (€5.8 million) to EMBL’s European Bioinformatics Institute (EMBL-EBI) to support the transfer of a large collection of information on the properties and activities of drugs and a large set of drug-like small molecules from the publicly listed…
2008
lab-matters
EMBL scientists found start-up company to develop anti-cancer drugs
Lab Matters Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…
2006
lab-matters
New potential drug target in tuberculosis
Science Tuberculosis remains one of the deadliest threats to public health. Every year two million people die of the disease, which is caused by the microorganism Mycobacterium tuberculosis. Roughly one third of the world’s population is infected and more and more bacterial strains have developed…
2006
science
Waking a sleeping virus
Science A detailed structural picture of a molecule that plays a key role in activating the Epstein Barr Virus in human cells has now been obtained by researchers at the European Molecular Biology Laboratory (EMBL) and the Institut de Virologie Moléculaire et Structurale (IVMS), associated with the…
2006
science
No matching posts found
